Presentation is loading. Please wait.

Presentation is loading. Please wait.

Fig. 6. N95BA5 biocompatibility beyond intended use frame.

Published byHadi Tan Modified over 5 years ago

Similar presentations

Presentation on theme: "Fig. 6. N95BA5 biocompatibility beyond intended use frame."— Presentation transcript:

1 Fig. 6. N95BA5 biocompatibility beyond intended use frame.
N95BA5 biocompatibility beyond intended use frame. (A) Series of histological cross sections prepared for control (left pairs) and treatment (right pairs) in hematoxylin and eosin (H&E) and Masson’s trichrome stain for each of the study endpoints (t = 48 hours, 1 week, and 4 week). Scale bars, 800 μm. (B) Increased magnification of one of the laceration margins for the treatment group showing evolution of the tissue-hydrogel interface from acute inflammatory infiltrate to a mature, compact fibrotic encapsulation layer at 4 weeks. Scale bars, 50 μm. (C) Gross visualization (top row) and high-magnification (bottom row) evaluation of treatment group retinas showing no evidence of trauma-induced retinal detachment or hydrogel-induced retinal neurotoxicity. Scale bars, 5 mm (top row) and 100 μm (bottom row). Niki Bayat et al., Sci Transl Med 2017;9:eaan3879 Published by AAAS

Download ppt "Fig. 6. N95BA5 biocompatibility beyond intended use frame."

Similar presentations

In vitro tissue engineering of a cardiac graft using a degradable scaffold with an extracellular matrix–like topography  Osamu Ishii, MD, Michael Shin,

In vitro tissue engineering of a cardiac graft using a degradable scaffold with an extracellular matrix–like topography  Osamu Ishii, MD, Michael Shin,
Fig. 1. TP is highly expressed in myeloma.

Fig. 1. TP is highly expressed in myeloma.
Kenichi Fujii et al. JIMG 2015;8:

Kenichi Fujii et al. JIMG 2015;8:
Fig. 2. LUM015 fluorescently labels tumor cells in mouse models of STS and breast cancer. LUM015 fluorescently labels tumor cells in mouse models of STS.

Fig. 2. LUM015 fluorescently labels tumor cells in mouse models of STS and breast cancer. LUM015 fluorescently labels tumor cells in mouse models of STS.
Fig. 3. Ultrasound-mediated BMP-6 gene delivery to mini-pig tibial bone fractures. Ultrasound-mediated BMP-6 gene delivery to mini-pig tibial bone fractures.

Fig. 3. Ultrasound-mediated BMP-6 gene delivery to mini-pig tibial bone fractures. Ultrasound-mediated BMP-6 gene delivery to mini-pig tibial bone fractures.
Fig. 6. AZD6738 induces DNA damage and apoptosis and exhibits antitumor efficacy in xenograft models of high-risk medulloblastoma and neuroblastoma. AZD6738.

Fig. 6. AZD6738 induces DNA damage and apoptosis and exhibits antitumor efficacy in xenograft models of high-risk medulloblastoma and neuroblastoma. AZD6738.
Fig. 3. Features of PH in KRasLA2 transgenic mice.

Fig. 3. Features of PH in KRasLA2 transgenic mice.
Fig. 4. Intramuscular injection of AAV9-Cas9/sgRNA-51 corrects dystrophin expression. Intramuscular injection of AAV9-Cas9/sgRNA-51 corrects dystrophin.

Fig. 4. Intramuscular injection of AAV9-Cas9/sgRNA-51 corrects dystrophin expression. Intramuscular injection of AAV9-Cas9/sgRNA-51 corrects dystrophin.
Fig. 6. Ex vivo and in vivo test to evaluate the sealing capability of the MeTro sealant using a porcine lung incision model. Ex vivo and in vivo test.

Fig. 6. Ex vivo and in vivo test to evaluate the sealing capability of the MeTro sealant using a porcine lung incision model. Ex vivo and in vivo test.
Fig. 4. Liver HBV mRNA paired-end sequencing reads in HBeAg-positive and HBeAg-negative chimpanzees. Liver HBV mRNA paired-end sequencing reads in HBeAg-positive.

Fig. 4. Liver HBV mRNA paired-end sequencing reads in HBeAg-positive and HBeAg-negative chimpanzees. Liver HBV mRNA paired-end sequencing reads in HBeAg-positive.
Fig. 4. Hydrogel particle size and gelation mechanism.

Fig. 4. Hydrogel particle size and gelation mechanism.
Fig. 1 Localized treatment of TNBC cancers kills tumor cells and minimizes the metastatic burden. Localized treatment of TNBC cancers kills tumor cells.

Fig. 1 Localized treatment of TNBC cancers kills tumor cells and minimizes the metastatic burden. Localized treatment of TNBC cancers kills tumor cells.
Fig. 4. Prion infectivity of skin samples from sCJD patients.

Fig. 4. Prion infectivity of skin samples from sCJD patients.
Fig. 3. Serum HBsAg and liver HBV mRNA reduction in chimpanzees dosed with ARC-520. Serum HBsAg and liver HBV mRNA reduction in chimpanzees dosed with.

Fig. 3. Serum HBsAg and liver HBV mRNA reduction in chimpanzees dosed with ARC-520. Serum HBsAg and liver HBV mRNA reduction in chimpanzees dosed with.
Fig. 1. NASH and fibrosis develop late in mice fed an HFD.

Fig. 1. NASH and fibrosis develop late in mice fed an HFD.
Fig. 8. mRIPO elicits neutrophil influx followed by DC and T cell infiltration into tumors. mRIPO elicits neutrophil influx followed by DC and T cell infiltration.

Fig. 8. mRIPO elicits neutrophil influx followed by DC and T cell infiltration into tumors. mRIPO elicits neutrophil influx followed by DC and T cell infiltration.
Fig. 4 Topical application of SAAP-148 ointment eradicates acute and established infections of MRSA and A. baumannii from the skin. Topical application.

Fig. 4 Topical application of SAAP-148 ointment eradicates acute and established infections of MRSA and A. baumannii from the skin. Topical application.
Fig. 4. Characterization of human liver seed graft morphology.

Fig. 4. Characterization of human liver seed graft morphology.
Fig. 4 Bone tissue formation within the Ti-mesh channels.

Fig. 4 Bone tissue formation within the Ti-mesh channels.
Fig. 5. Immunohistochemistry of the tumor microenvironment in GBM specimens before and after CART-EGFRvIII infusion. Immunohistochemistry of the tumor.

Fig. 5. Immunohistochemistry of the tumor microenvironment in GBM specimens before and after CART-EGFRvIII infusion. Immunohistochemistry of the tumor.

Similar presentations

Ads by Google